Syndax Pharmaceuticals, Inc. is a biopharmaceutical company focused on the development and commercialization of the Company's lead product candidate, entinostat, an epigenetic therapy for treatment-resistant cancers. The Company and its collaborators at the National Cancer Institute (NCI) will evaluate entinostat in a pivotal Phase III clinical trial in hormone receptor, (HR), positive locally advanced or metastatic breast cancer, which it refers to as advanced breast cancer. Entinostat is an oral histone deacetylase (HDAC) inhibitor of the benzamide chemical class of compounds. The Company is initially focused on the treatment of HR-positive men and postmenopausal women with advanced breast cancer who has progressed after standard of care hormonal agents. Its lung cancer program is focused on advancing two combination approaches shown in preclinical studies to inhibit lung cancer cell growth.